This is an open-label, randomized, single-dose, double-crossover bioequivalence study comparing a single oral dose of two strengths of IMP4297 capsules (10 mg and 20 mg) in healthy Chinese subjects under fasting state.
Latest Information Update: 21 Jan 2025
Price :
$35 *
At a glance
- Drugs Senaparib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- 21 Jan 2025 New trial record